Michal Mielcarek

List of Publications by Year
in descending order

35 papers	1,381 citations	361045 20 h-index	395343 33 g-index
36 all docs	36 docs citations	36 times ranked	1778 citing authors

#	Article	IF	Citations
1	HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration. PLoS Biology, 2013, 11, e1001717.	2.6	143
2	SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease. PLoS ONE, 2011, 6, e27746.	1.1	137
3	Skeletal muscle pathology in Huntington's disease. Frontiers in Physiology, 2014, 5, 380.	1.3	91
4	Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Frontiers in Medicine, 2021, 8, 809118.	1.2	91
5	HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. Frontiers in Cellular Neuroscience, 2015, 9, 42.	1.8	90
6	Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease. PLoS Genetics, 2014, 10, e1004550.	1.5	83
7	Update on Huntington's disease: Advances in care and emerging therapeutic options. Parkinsonism and Related Disorders, 2015, 21, 169-178.	1.1	61
8	Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease. PLoS ONE, 2009, 4, e5747.	1.1	61
9	VITO-1 is an essential cofactor of TEF1-dependent muscle-specific gene regulation. Nucleic Acids Research, 2004, 32, 791-802.	6.5	59
10	HDAC4-Myogenin Axis As an Important Marker of HD-Related Skeletal Muscle Atrophy. PLoS Genetics, 2015, 11, e1005021.	1.5	56
11	VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage. Mechanisms of Development, 2002, 119, S269-S274.	1.7	52
12	Identification of 6-Furfuryladenine (Kinetin) in Human Urine. Biochemical and Biophysical Research Communications, 2000, 279, 69-73.	1.0	48
13	Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Molecular Neurodegeneration, 2016, 11, 64.	4.4	46
14	Huntington's disease is a multi-system disorder. Rare Diseases (Austin, Tex), 2015, 3, e1058464.	1.8	42
15	An impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington's disease related cardiomyopathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 2147-2157.	1.8	42
16	Neuro-Cardio Mechanisms in Huntingtonâ€™s Disease and Other Neurodegenerative Disorders. Frontiers in Physiology, 2018, 9, 559.	1.3	40
17	HDAC4 Does Not Act as a Protein Deacetylase in the Postnatal Murine Brain In Vivo. PLoS ONE, 2013, 8, e80849.	1.1	30
18	The Huntington's Disease-Related Cardiomyopathy Prevents a Hypertrophic Response in the R6/2 Mouse Model. PLoS ONE, 2014, 9, e108961.	1.1	29

#	Article	IF	Citations
19	VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development. Gene Expression Patterns, 2009, 9, 129-137.	0.3	28
20	A shared mechanism of muscle wasting in cancer and Huntington's disease. Clinical and Translational Medicine, 2015, 4, 34.	1.7	22
21	Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington's Disease Mouse Model. Frontiers in Physiology, 2017, 8, 127.	1.3	22
22	Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy. PLoS ONE, 2017, 12, e0180571.	1.1	18
23	Changes in cardiac nucleotide metabolism in Huntington's disease. Nucleosides, Nucleotides and Nucleic Acids, 2016, 35, 707-712.	0.4	13
24	Prevalence of Non-psychiatric Comorbidities in Pre-symptomatic and Symptomatic Huntington's Disease Gene Carriers in Poland. Frontiers in Medicine, 2020, 7, 79.	1.2	12
25	Native transfer RNA catalyzes Dielsâ€“Alder reaction. Biochemical and Biophysical Research Communications, 2002, 294, 145-148.	1.0	11
26	M09 Myostatin Inhibition as a Novel Approach to Targeting Muscle Pathology in HD. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, A97-A97.	0.9	7
27	Oxidized low-density lipoproteins enhance expression and activity of CD39 and CD73 in the human aortic valve endothelium. Nucleosides, Nucleotides and Nucleic Acids, 2016, 35, 713-719.	0.4	6
28	Structural Abnormalities of the Optic Nerve and Retina in Huntingtonâ€™s Disease Pre-Clinical and Clinical Settings. International Journal of Molecular Sciences, 2022, 23, 5450.	1.8	6
29	Cross-Sectional Transcriptional Analysis of the Aging Murine Heart. Frontiers in Molecular Biosciences, 2020, 7, 565530.	1.6	5
30	Kinetin stimulates differentiation of C2C12 myoblasts. PLoS ONE, 2021, 16, e0258419.	1.1	5
31	Polyglutamine diseases: looking beyond the neurodegenerative universe. Neural Regeneration Research, 2021, 16, 1186.	1.6	3
32	Identification of the Transcriptional Biomarkers Panel Linked to Pathological Remodelling of the Eye Tissues in Various HD Mouse Models. Cells, 2022, 11, 1675.	1.8	2
33	A12â€…HDAC4 interacts with huntington and HDAC4 reduction decreases cytoplamsic aggregation and rescues synaptic dysfunction in HD mouse models. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A4.1-A4.	0.9	0
34	B44 The Cns-heart Axis Is A Source Of Cardiac Dysfunction In Mouse Models Of Huntington's Disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, A24-A24.	0.9	0
35	A35â€…An altered metabolism of nucleotides leads to huntingtonâ€™s disease related cardiomyopathy. , 2018, , .		0